A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 25 Aug 2017 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.
- 25 Aug 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Feb 2019.
- 20 Apr 2017 Results from this trial will be presented at the American Academy of Neurology (AAN) annual meeting 2017, as reported in an Eli Lilly and Company media release.